因塞特醫療 INCY 深 滬
已收盤 02-06 16:00:00 美东时间
108.39
+5.630
+5.48%
華盛通- 最 高108.52
- 今 開103.75
- 成交量 219.39万股
- 最 低 103.52
- 昨 收 102.76
- 總市值 212.79亿
- 52周最高 112.29
- 市盈率 靜 699.74
- 換手率 1.12%
- 52周最低 53.56
- 委 比 -88.98%
- 總股本 1.96亿
- 歷史最高 153.15
- 量 比 1.21
- 振 幅 4.87%
- 歷史最低 11.76
- 每 手 1
- 風險率 15.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 谷歌绩后获14家大行上调目标价；Arm、高通、波士顿科学、艾可菲、Snap、优步遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Wave Life Sciences Ltd."超配"评级，目标价从34美元升至41美元；Piper Sandler：维持Replimune Group"超配"评级，目标价从13美元升至14美元
02-06 16:52
华尔街顶级分析师最新评级：微软遭下调，Snap获上调
华尔街最受关注、能推动市场走势的研究报告现已汇总于此。以下由 The Fly 整理的今日投资者需重点关注的分析师评级调整。 五大上调评级 B． Rile...
02-06 00:40
美股大行评级 | 泰瑞达、Lumentum、哈贝尔、Enphase能源、西部数据获多家机构上调目标价；PayPal 、恩智浦、墨式烧烤遭多家机构下调目标价
今日重点评级关注：韦德布什：维持Replimune Group"跑赢大市"评级，目标价从18美元升至19美元；巴克莱：维持CytomX Therapeutics"超配"评级，目标价从8美元升至10美元
02-05 11:28
Tafasitamab-Parsaclisib Trial Termination Tempers Incyte Outlook
Incyte ($INCY) announced an update on their ongoing clinical study. Tafasitamab...
02-05 00:30
Barclays Maintains Overweight on Incyte, Raises Price Target to $116
Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $115 to $116.
02-04 22:24
U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico
U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico Feb 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ametek, Coca-Cola and Pepsico, on Wednesday. HIGHLIGHTS * Ametek AME.N : RBC raises target price to $257 from $229 *
02-04 14:59
FDA Clears Prelude Therapeutics' IND Application for JAK2V617F Inhibitor PRT12396
FDA Clears Prelude Therapeutics' IND Application for JAK2V617F Inhibitor PRT12396 Prelude Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor. The company plans to
02-03 22:00
Incyte Gets Positive Opinion From Medicinal Products For Human Use Of European Medicines Agency For Approval Of Zynyz
Incyte (NASDAQ:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz®
01-30 22:39
EMA Panel Recommends Approval of Incyte's Zynyz for Advanced Anal Cancer
EMA Panel Recommends Approval of Incyte's Zynyz for Advanced Anal Cancer Incyte Corporation announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination
01-30 22:29
Incyte Corporation published an update to their financial calendar
Incyte Corporation published an update to their financial calendar Incyte Corporation will release its fourth quarter and year-end 2025 financial results on February 10, 2026, at 7:00 a.m. ET. A conference call and webcast to discuss the results will be held on the same day at 8:00 a.m. ET. The live
01-28 01:15
